Abstract
Cushing disease is caused by a corticotroph tumor of the pituitary gland. Patients with Cushing disease are usually treated with transsphenoidal surgery, as this approach leads to remission in 70–90% of cases and is associated with low morbidity when performed by experienced pituitary gland surgeons. Nonetheless, among patients in postoperative remission, the risk of recurrence of Cushing disease could reach 20–25% at 10 years after surgery. Patients with persistent or recurrent Cushing disease might, therefore, benefit from a second pituitary operation (which leads to remission in 50–70% of cases), radiation therapy to the pituitary gland or bilateral adrenalectomy. Remission after radiation therapy occurs in ∼85% of patients with Cushing disease after a considerable latency period. Interim medical therapy is generally advisable after patients receive radiation therapy because of the long latency period. Bilateral adrenalectomy might be considered in patients who do not improve following transsphenoidal surgery, particularly patients who are very ill and require rapid control of hypercortisolism, or those wishing to avoid the risk of hypopituitarism associated with radiation therapy. Adrenalectomized patients require lifelong adrenal hormone replacement and are at risk of Nelson syndrome. The development of medical therapies with improved efficacy might influence the management of this challenging condition.
Key Points
-
Transsphenoidal surgery is advisable for most patients with newly diagnosed Cushing disease and often leads to rapid and sustained remission of hypercortisolism with low morbidity in most cases
-
Pituitary reoperation might be considered in patients with persistent or recurrent Cushing disease, but the remission rate is lower in comparison to initial surgery
-
Pituitary gland radiation therapy might lead to remission in many patients with persistent or recurrent Cushing disease, but takes a considerable time and a lifelong risk of hypopituitarism exists
-
Medical therapy can be used in patients who are awaiting the therapeutic effects of pituitary gland radiation therapy or in very ill patients in preparation for surgery
-
Bilateral adrenalectomy could be considered in patients with persistent or recurrent Cushing disease to control hypercortisolism, but will induce adrenal insufficiency and carries the risk of Nelson syndrome
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cushing, H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull. Johns Hopkins Hosp. 50, 137–195 (1932).
Cushing, H. The basophil adenomas of the pituitary body. Ann. R. Coll. Surg. Engl. 44, 180–181 (1969).
Nieman, L. K. & Ilias, I. Evaluation and treatment of Cushing's syndrome. Am. J. Med. 118, 1340–1346 (2005).
Raff, H. & Findling, J. W. A physiologic approach to diagnosis of the Cushing syndrome. Ann. Intern. Med. 138, 980–991 (2003).
Arnaldi, G. et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003).
Biller, B. M. et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93, 2454–2462 (2008).
Nieman, L. K. et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008).
Bonneville, J. F., Cattin, F., Bonneville, F., Schillo, F. & Jacquet, G. Pituitary gland imaging in Cushing's disease [French]. Neurochirurgie 48, 173–185 (2002).
Dwyer, A. J. et al. Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. Radiology 163, 421–426 (1987).
Hardy, J. Excision of pituitary adenomas by trans-sphenoidal approach [French]. Union Med. Can. 91, 933–945 (1962).
Oldfield, E. H. et al. Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N. Engl. J. Med. 312, 100–103 (1985).
Oldfield, E. H. et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N. Engl. J. Med. 325, 897–905 (1991).
Barker, F. G. 2nd, Klibanski, A. & Swearingen, B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J. Clin. Endocrinol. Metab. 88, 4709–4719 (2003).
Semple, P. L. & Laws, E. R. Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. J. Neurosurg. 91, 175–179 (1999).
Swearingen, B. et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann. Intern. Med. 130, 821–824 (1999).
Fitzgerald, P. A. et al. Cushing's disease: transient secondary adrenal insufficiency after selective removal of pituitary microadenomas; evidence for a pituitary origin. J. Clin. Endocrinol. Metab. 54, 413–422 (1982).
Ram, Z. et al. Early repeat surgery for persistent Cushing's disease. J. Neurosurg. 80, 37–45 (1994).
Patil, C. G. et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J. Clin. Endocrinol. Metab. 93, 358–362 (2008).
Sonino, N., Zielezny, M., Fava, G. A., Fallo, F. & Boscaro, M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J. Clin. Endocrinol. Metab. 81, 2647–2652 (1996).
Invitti, C. et al. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J. Clin. Endocrinol. Metab. 84, 440–448 (1999).
Hammer, G. D. et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 89, 6348–6357 (2004).
Rollin, G. A., Ferreira, N. P., Junges, M., Gross, J. L. & Czepielewski, M. A. Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing's disease. J. Clin. Endocrinol. Metab. 89, 1131–1139 (2004).
Shimon, I., Ram, Z., Cohen, Z. R. & Hadani, M. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51, 57–62 (2002).
Carrasco, C. A. et al. Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. J. Clin. Endocrinol. Metab. 93, 4728–4734 (2008).
Bochicchio, D., Losa, M. & Buchfelder, M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J. Clin. Endocrinol. Metab. 80, 3114–3120 (1995).
Rees, D. A. et al. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin. Endocrinol. (Oxf.) 56, 541–551 (2002).
Chee, G. H., Mathias, D. B., James, R. A. & Kendall-Taylor, P. Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome? Clin. Endocrinol. (Oxf.) 54, 617–626 (2001).
Guilhaume, B. et al. Transsphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long term follow-up studies. J. Clin. Endocrinol. Metab. 66, 1056–1064 (1988).
Blevins, L. S. Jr, Christy, J. H., Khajavi, M. & Tindall, G. T. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab. 83, 63–67 (1998).
Yap, L. B., Turner, H. E., Adams, C. B. & Wass, J. A. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin. Endocrinol. (Oxf.) 56, 25–31 (2002).
Dehdashti, A. R. & Gentili, F. Current state of the art in the diagnosis and surgical treatment of Cushing disease: early experience with a purely endoscopic endonasal technique. Neurosurg. Focus. 23, E9 (2007).
Zada, G., Governale, L. S. & Laws, E. R. Jr. Intraoperative conversion from endoscopic to microscopic approach for the management of sellar pathology: incidence and rationale in a contemporary series. World Neurosurg. 73, 334–337 (2010).
Trainer, P. J. et al. Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin. Endocrinol. (Oxf.) 38, 73–78 (1993).
Estrada, J. et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J. Clin. Endocrinol. Metab. 86, 5695–5699 (2001).
Esposito, F. et al. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J. Clin. Endocrinol. Metab. 91, 7–13 (2006).
Chen, J. C. et al. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J. Neurosurg. 98, 967–973 (2003).
Barbetta, L. et al. Assessment of cure and recurrence after pituitary surgery for Cushing's disease. Acta Neurochir. (Wien.) 143, 477–482 (2001).
Avgerinos, P. C. et al. The corticotropin-releasing hormone test in the postoperative evaluation of patients with cushing's syndrome. J. Clin. Endocrinol. Metab. 65, 906–913 (1987).
Castinetti, F. et al. A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing's disease. J. Clin. Endocrinol. Metab. 94, 1897–1903 (2009).
van Aken, M. O., de Herder, W. W., van der Lely, A. J., de Jong, F. H. & Lamberts, S. W. Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin. Endocrinol. (Oxf.) 47, 145–149 (1997).
Pereira, A. M. et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J. Clin. Endocrinol. Metab. 88, 5858–5864 (2003).
Nunes, M. L. et al. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. J. Clin. Endocrinol. Metab. 94, 456–462 (2009).
Tani, Y. et al. Ectopic ACTH syndrome caused by bronchial carcinoid tumor indistinguishable from Cushing's disease. Endocr. J. 57, 679–686 (2010).
Valassi, E. et al. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J. Clin. Endocrinol. Metab. 95, 601–610 (2010).
Patil, C. G. et al. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 63, 266–271 (2008).
Estrada, J. et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N. Engl. J. Med. 336, 172–177 (1997).
Littley, M. D. et al. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin. Endocrinol. (Oxf.) 33, 445–455 (1990).
Laws, E. R. Jr & Vance, M. L. Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg. Clin. N. Am. 10, 327–336 (1999).
Sheehan, J. M., Vance, M. L., Sheehan, J. P., Ellegala, D. B. & Laws, E. R. Jr. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J. Neurosurg. 93, 738–742 (2000).
Colin, P. et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int. J. Radiat. Oncol. Biol. Phys. 62, 333–341 (2005).
Devin, J. K. et al. The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease. Stereotact. Funct. Neurosurg. 82, 254–262 (2004).
Levy, R. P. et al. Heavy-charged-particle radiosurgery of the pituitary gland: clinical results of 840 patients. Stereotact. Funct. Neurosurg. 57, 22–35 (1991).
Petit, J. H. et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J. Clin. Endocrinol. Metab. 93, 393–399 (2008).
Minniti, G. et al. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J. Neurooncol. 84, 79–84 (2007).
Castinetti, F. et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur. J. Endocrinol. 156, 91–98 (2007).
Landolt, A. M. et al. Octreotide may act as a radioprotective agent in acromegaly. J. Clin. Endocrinol. Metab. 85, 1287–1289 (2000).
Feigl, G. C., Bonelli, C. M., Berghold, A. & Mokry, M. Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J. Neurosurg. 97 (Suppl.), 415–421 (2002).
Sheehan, J. P. et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J. Neurosurg. 102, 678–691 (2005).
Brada, M. et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin. Endocrinol. (Oxf.) 38, 571–578 (1993).
Minniti, G., Traish, D., Ashley, S., Gonsalves, B. & Brada, M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J. Clin. Endocrinol. Metab. 90, 800–804 (2005).
Nieman, L. K. Medical therapy of Cushing's disease. Pituitary 5, 77–82 (2002).
Schteingart, D. E. Drugs in the medical treatment of Cushing's syndrome. Expert Opin. Emerg. Drugs. 14, 661–671 (2009).
Sonino, N., Boscaro, M., Paoletta, A., Mantero, F. & Ziliotto, D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin. Endocrinol. (Oxf.) 35, 347–352 (1991).
McCance, D. R., Ritchie, C. M., Sheridan, B. & Atkinson, A. B. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1, 573 (1987).
Tabarin, A. et al. Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clin. Endocrinol. (Oxf.) 34, 63–69 (1991).
Verhelst, J. A. et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin. Endocrinol. (Oxf.) 35, 169–178 (1991).
Gormley, M. J. et al. Cushing's syndrome in pregnancy—treatment with metyrapone. Clin. Endocrinol. (Oxf.) 16, 283–293 (1982).
Lindsay, J. R., Jonklaas, J., Oldfield, E. H. & Nieman, L. K. Cushing's syndrome during pregnancy: personal experience and review of the literature. J. Clin. Endocrinol. Metab. 90, 3077–3083 (2005).
Luton, J. P. et al. Treatment of Cushing's disease by o,p'DDD. Survey of 62 cases. N. Engl. J. Med. 300, 459–464 (1979).
Leiba, S. et al. The protracted effect of o, p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann. Endocrinol. (Paris) 50, 49–53 (1989).
Allolio, B. et al. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin. Wochenschr. 66, 361–364 (1988).
Schulte, H. M., Benker, G., Reinwein, D., Sippell, W. G. & Allolio, P. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J. Clin. Endocrinol. Metab. 70, 1426–1430 (1990).
Thorén, M., Adamson, U. & Sjöberg, H. E. Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol. (Copenh.) 109, 451–457 (1985).
Dewis, P., Anderson, D. C., Bu'lock, D. E., Earnshaw, R. & Kelly, W. F. Experience with trilostane in the treatment of Cushing's syndrome. Clin. Endocrinol. (Oxf.) 18, 533–540 (1983).
Klibanski, A. Clinical practice. Prolactinomas. N. Engl. J. Med. 362, 1219–1226 (2010).
de Bruin, C., Feelders, R. A., Lamberts, S. W. & Hofland, L. J. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev. Endocr. Metab. Disord. 10, 91–102 (2009).
Pivonello, R. et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94, 223–230 (2009).
Godbout, A. et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur. J. Endocrinol. 163, 709–716 (2010).
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. & Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29–38 (2007).
Zanettini, R. et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39–46 (2007).
Valassi, E., Klibanski, A. & Biller, B. M. Clinical Review: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95, 1025–1033 (2010).
Ben-Shlomo, A. et al. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94, 4342–4350 (2009).
Boscaro, M. et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94, 115–122 (2009).
Feelders, R. A. et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N. Engl. J. Med. 362, 1846–1848 (2010).
Vilar, L. et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 13, 123–129 (2010).
Kreutzer, J. et al. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. Clin. Neuropathol. 28, 430–439 (2009).
Castinetti, F. et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur. J. Endocrinol. 160, 1003–1010 (2009).
Porterfield, J. R. et al. Surgery for Cushing's syndrome: an historical review and recent ten-year experience. World J. Surg. 32, 659–677 (2008).
Vella, A. et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome. J. Clin. Endocrinol. Metab. 86, 1596–1599 (2001).
Chapuis, Y., Chastanet, S., Dousset, B. & Luton, J. P. Bilateral laparoscopic adrenalectomy for Cushing's disease. Br. J. Surg. 84, 1009 (1997).
Smith, P. W. et al. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J. Am. Coll. Surg. 208, 1059–1064 (2009).
Thompson, S. K. et al. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann. Surg. 245, 790–794 (2007).
Nagesser, S. K. et al. Long-term results of total adrenalectomy for Cushing's disease. World J. Surg. 24, 108–113 (2000).
Thompson, G. B. et al. Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 122, 1132–1136 (1997).
Chow, J. T. et al. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin. Endocrinol. (Oxf.) 68, 513–519 (2008).
Assalia, A. & Gagner, M. Laparoscopic adrenalectomy. Br. J. Surg. 91, 1259–1274 (2004).
Nelson, D. H. et al. ACTH-producing tumor of the pituitary gland. N. Engl. J. Med. 259, 161–164 (1958).
Assié, G. et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: a reappraisal of Nelson's Syndrome. J. Clin. Endocrinol. Metab. 92, 172–179 (2007).
De Tommasi, C., Vance, M. L., Okonkwo, D. O., Diallo, A. & Laws, E. R. Jr. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. J. Neurosurg. 103, 825–830 (2005).
Vik-Mo, E. O. et al. Gamma knife stereotactic radiosurgery of Nelson syndrome. Eur. J. Endocrinol. 160, 143–148 (2009).
Yanovski, J. A., Cutler, G. B. Jr, Chrousos, G. P. & Nieman, L. K. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269, 2232–2238 (1993).
Valassi, E. et al. Concomitant medication use can confound Interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome. J. Clin. Endocrinol. Metab. 94, 4851–4859 (2009).
Doppman, J. L. et al. Gadolinium DTPA enhanced MR imaging of ACTH-secreting microadenomas of the pituitary gland. J. Comput. Assist. Tomogr. 12, 728–735 (1988).
Hall, W. A., Luciano, M. G., Doppman, J. L., Patronas, N. J. & Oldfield, E. H. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann. Intern. Med. 120, 817–820 (1994).
Nieman, L. K. et al. The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann. Intern. Med. 105, 862–867 (1986).
Bakiri, F. et al. Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. J. Endocrinol. Invest. 19, 572–580 (1996).
Knappe, U. J. & Lüdecke, D. K. Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease. Acta Neurochir. Suppl. 65, 31–34 (1996).
Cavagnini, F. & Pecori Giraldi, F. Epidemiology and follow-up of Cushing's disease. Ann. Endocrinol. (Paris) 62, 168–172 (2001).
Flitsch, J., Knappe, U. J. & Lüdecke, D. K. The use of postoperative ACTH levels as a marker for successful transsphenoidal microsurgery in Cushing's disease. Zentralbl Neurochir. 64, 6–11 (2003).
Salenave, S. et al. Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. J. Clin. Endocrinol. Metab. 89, 3371–3376 (2004).
Atkinson, A. B., Kennedy, A., Wiggam, M. I., McCance, D. R. & Sheridan, B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin. Endocrinol. (Oxf.) 63, 549–559 (2005).
Hofmann, B. M. & Fahlbusch, R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front. Horm. Res. 34, 158–184 (2006).
Acebes, J. J., Martino, J., Masuet, C., Montanya, E. & Soler, J. Early post-operative ACTH and cortisol as predictors of remission in Cushing's disease. Acta Neurochir. (Wien.) 149, 471–479 (2007).
Rollin, G., Ferreira, N. P. & Czepielewski, M. A. Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing's disease. Arq. Bras. Endocrinol. Metabol. 51, 1355–1361 (2007).
Hofmann, B. M. et al. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J. Neurosurg. 108, 9–18 (2008).
Prevedello, D. M. et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J. Neurosurg. 109, 751–759 (2008).
Fomekong, E., Maiter, D., Grandin, C. & Raftopoulos, C. Outcome of transsphenoidal surgery for Cushing's disease: a high remission rate in ACTH-secreting macroadenomas. Clin. Neurol. Neurosurg. 111, 442–449 (2009).
Jagannathan, J. et al. Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J. Neurosurg. 111, 531–539 (2009).
Murayama, M. et al. Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation. J. Clin. Endocrinol. Metab. 75, 935–942 (1992).
Tsang, R. W. et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother. Oncol. 41, 45–53 (1996).
Witt, T. C., Kondziolka, D., Flickinger, J. C. & Lunsford, L. D. in Gamma knife radiosurgery for pituitary tumors (eds Lunsford, L. D., Kondziolka, D. & Flickinger, J. C.) 114–127 (Karger, Basel, 1998).
Kobayashi, T., Kida, Y. & Mori, Y. Gamma knife radiosurgery in the treatment of Cushing disease: long-term results. J. Neurosurg. 97, 422–428 (2002).
Jagannathan, J. et al. Gamma Knife surgery for Cushing's disease. J. Neurosurg. 106, 980–987 (2007).
Acknowledgements
C. P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Contributions
All authors contributed equally to all aspects of this review.
Corresponding author
Ethics declarations
Competing interests
B. M. K. Biller has been a consultant for Novartis and has received grant/research support from Corcept and Novartis. B. Swearingen has been a consultant for Novartis. N. A. Tritos declares no competing interests.
Rights and permissions
About this article
Cite this article
Tritos, N., Biller, B. & Swearingen, B. Management of Cushing disease. Nat Rev Endocrinol 7, 279–289 (2011). https://doi.org/10.1038/nrendo.2011.12
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.12
This article is cited by
-
Cushing’s disease: risk of recurrence following trans-sphenoidal surgery, timing and methods for evaluation
Pituitary (2022)
-
Surgical outcome of transsphenoidal surgery in Cushing’s disease: a case series of 1106 patients from a single center over 30 years
Endocrine (2022)
-
Surgical strategies in the treatment of MR-negative Cushing’s Disease: a systematic review and treatment algorithm
Pituitary (2022)
-
Treatment of recurrent and persistent Cushing’s disease after first transsphenoidal surgery: lessons learned from an international meta-analysis
Pituitary (2022)
-
A challenging case of Cushing’s disease complicated with multiple thrombotic phenomena following trans-sphenoidal surgery; a case report
BMC Endocrine Disorders (2021)